Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice | Zendy

Jian Yang | Zendy; Yun Mou | Zendy; Tao Wu | Zendy; Yang Ye | Zendy; Junchang Jiang | Zendy; Chenze Zhao | Zendy; Huanhuan Zhu | Zendy; Changqing Du | Zendy; Liang Zhou | Zendy; ShenJiang Hu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiac-specific overexpression of farnesyl pyrophosphate synthase induces cardiac hypertrophy and dysfunction in mice

Author(s) -

Jian Yang,

Yun Mou,

Tao Wu,

Yang Ye,

Junchang Jiang,

Chenze Zhao,

Huanhuan Zhu,

Changqing Du,

Liang Zhou,

ShenJiang Hu

Publication year - 2012

Publication title -

cardiovascular research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.774

H-Index - 219

eISSN - 1755-3245

pISSN - 0008-6363

DOI - 10.1093/cvr/cvs347

Subject(s) - farnesyl pyrophosphate , rhoa , medicine , mevalonate pathway , kinase , muscle hypertrophy , chemistry , signal transduction , endocrinology , microbiology and biotechnology , biology , biochemistry , atp synthase , enzyme , reductase

Farnesyl pyrophosphate synthase (FPPS) is a key enzyme in the mevalonate pathway. In our previous study, we found that inhibition of FPPS attenuates cardiac hypertrophy in spontaneously hypertensive rats (SHRs) and prevents angiotensin (Ang) II-induced hypertrophy in cardiomyocytes. Here, we further investigate the role of FPPS in cardiac hypertrophy and heart failure (HF) using a transgenic (Tg) model, and its mechanisms.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research